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In plasma, Factor VIII is bound to its carrier protein, von Willebrand Factor (vWF). Therefore,
the levels ofthese two factors vary together. From studies in the general population, in patients with
coronary heart disease and in hemophilia patients, an association between Factor VIII levels and
coronary heart disease clearly emerges.
INTRODUCTION
In the last decade it has become increasingly clear
that the hemostatic System plays a central role in the
development of coronary heart disease. Not only has it
been demonstrated that coronary thrombosis is the
final and crucial event in myocardial infarction (4, 5),
but also that hypercoagulability, i.e. high blood levels
of clotting factors, are long term predictors of
coronary heart disease. In the Nortwick Park Heart
Study it was prospectively shown that the levels of
clotting factor VII and fibrinogen were strongly
related to the risk of the development of myocardial
infarction (12). These associations have been
confirmed in several other studies (2, 8, 23).
The presence of occlusing thrombi in the
coronary arteries causing myocardial infarction and
the predictive power of factor VII and fibronogen
establish the role of coagulation in coronary heart
disease. With regard to fibrinogen, it has to be noted
that this protein contibutes substantially to blood
viscosity. Hyperfibrinogenemia, therefore, leads to
hyperviscosity äs well äs hypercoagulability, which
may also explain the association with coronary heart
disease. Further evidence for the clotting System äs a
major determinant of coronary heart disease is
provided by the efficacy of oral anticoagulation in the
prevention of recurrent myocardial infarction (20, 21).
In this paper we wiH consider the role of clotting
factor VIII. In response to tissue damage, blood
coagulation is initiated by factor VII in combination with
cell surface bound tissue factor and phospholipid
surfaces. In the initial phase factor X is activated and the
product, factor Xa activates factor VII into factor Vita,
which has higher enzymatic potency that its precursor.
Subsequently, the process follows the alternative pathway
where factor IX is activated by factor Vlla and factor X is
activated predominantly by factor IXa. Finally, factor
Xa activates prothrombin into thrombin, the major
effector enzyme of the system (Figure 1).
The three enzymes Vlla, IXa and Xa require non-
enzymatic cofactors for their catalytic efficiency: tissue
factor, factor VIII and factor V, respectively. A
powerful positive feedback is provided by thrombin
activating factor VIII to Villa and factor V to Va.
Since hemophilia A, hereditary factor VIII deficiency,
is associated with severe bleeding, we know that factor
VIII is an essential component of the System.
In plasma, factor VIII is bound to its carrier
protein, von Willebrand factor (vWF). The levels of
these two factors covary and are related to blood
group. Since von Willebrand factor may itself be a
determinant of the risk of CHD, given its function in
promoting platelet adhesion, this covariation poses a
Problem in evaluating studies on factor VIII levels and
coronary heart disease.
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Figure 1. - The central pari of the clotting System.
Blood group, factor VIII and von Willebrand factor
Since von Willebrand factor is the carrier protein
of factor VIII,, low levels of vWF äs in von
Willebrand's disease, cause a shortened half-life of
factor VIII and low plasma levels of factor VIII. This
forms the main cause of bleeding problems in von
Willebrand's disease. In the normal population the
levels of both factors also vary together, and are
related to blood group. Table l shows this relation and
covariation by the results of a study we performed on
93 healthy volunteers.
In several studies a higher risk of coronary heart
disease (by about 20 percent), äs well äs of
atherosclerosis, has been demonstrated for individuals
with non-O blood groups (9, 13, 22). This is likely to
be caused by the higher levels osf von Willebrand
factor and factor VIII in these individuals (14).
TABLE 1. - Relation between blood group, FVIII and
vWf.
In this paper we will restrict ourselves to clotting
factor VIII. However, since platelet adhesion mediated by
von Willebrand factor may play a role in the pathogenesis
of myocardial infarction (6), this background Information
on the covariation of vWF and FVIII is essential in
interpreting the evidence on the relation between factor
VIII and coronary heart disease.
Types of studies
Three types of studies can be considered. First,
studies in the general population, in which baseline
measurements are associated with subsequent coronary
events. These are (prospective) cohort studies in initially
healthy individuals. Secondly, studies in patients with
coronary heart disease, in whom clotting factors are
measured after the disease has manifested itself. These
are studies in which the clotting factor levels of the
patients are compared to those of healthy controls.
Thirdly, studies in hemophilia patients, who lack factor
VIII. These are 'experiments of nature', in which the
frequency of coronary disease (or mortality) is compared
with the general population.
Cohort studies
At present there is only one completed
prospective cohort study in which factor VIII was
measured, The Northwick Park Heart Study (12),
whereas one study is still in progress (the PROCAM
study in Germany). Table 2 shows the relative risks for
myocardial infarction associated with different levels
of factor VIII that were observed in the 1500 men
followed in the Northwick Park Heart Study.
These results of the Northwick Park Heart Study
indicate that in the one third of the population with
the highest factor VIII levels, the risk of the
development of coronary heart disease may be äs
much äs 44 percent greater than in the one third of the
population with the lowest factor VIII levels, although
the association was not statistically significant (p =
0.2). Because of the covariation of factor VIII and von
Willebrand factor, this association might have been
brought about by a relation between vWF levels and
the risk of CHD. However, when mean values at entry
were compared for 15 cardiovascular deaths and 45
survivors, no differece in vWF levels was discerned (11).
Blood group
O non-O
(n = 40) (n = 53)
FVIII (IU / ml)
vWF (IlJ/ml)
Ratio FYIII / vWF
0.88
0.86
1.02
1.25
1.16
1.06
Normal mean for FVIII and vWF is 1.0 lU/ml. FVIII coagulant
activity (FVIILC) measured by a one-stage clotting assay, vWF
activity äs ristocetin cofactor activity (vWF:Rco) by the use of
formalin fixed platelets.
TABLE 2. - Risk of coronary heart disease and factor
VIII levels (Northwick Park Heart Study).
FVIII CHD relative risk
low
middle
high
27
36
39
1.00
1.33
1.44
The cohort was divided in thirds of the FVIII distribution. The
risk of CHD to the lowest third was calculated from the paper
under the assumption of equal follow-up time in all three groups.
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Studies in patients with coronary heart disease
If a high plasma concentration of factor VIII
increases the risk of CHD, one would expect higher
levels of factor VIII in patients with coronary disease
than in healthy individuals. Cucuianu and colleagues
reported elevated levels of FVIII and vWF shortly
after myocardial infarction (3). The observed clotting
factor levels in the patients were so high (two- to
fourfold increase) that the authors concluded that this
was most likely brought about by the infarction, either
äs the result of endothelial injury or äs a systemic
acute phase reaction. Haines et al. studied 272 patients
with myocardial infarction (7) and also observed
substantially elevated factor VIII levels (approx. 1.4
lU/ml, normal value 1.0 lU/ml) in these patients.
Subsequently, the patients were followed for one year.
The 68 patients who died had had a mean factor VIII
level of 1.65 lU/ml (at admission), whereas the 204
patients who were alive at one year had had a mean
factor VIII level of 1.27 ίο/ml Von Willebrand factor
levels were also higher in the patients than the
Population mean, and also had prognostic value in the
one year follow-up. In this paper too it was discussed
that the raised clotting factor levels might have
resulted from the infarction, and that the extent of the
elevation might be a reflection of infarction size, thus
offering an alternative explanation than
hypercoagulability for the prognostic value of factor
VIII levels after myocardial infarction.
Studies in heniophilia patients
Hemophilia A, which accounts for 85% of all
cases of hemophilia, is a deficiency of factor VIII.
Factor VIII may be completely absent, äs in severe
hemophilia, or present to some extent, äs in moderate
and mild hemophilia. Von Willebrand factor and
platelet function is not affected in hemophilia. Until
the 1960s, before the introduction of cryoprecipitate,
hemophilia could not be adequately treated, and most
patients died of bleeding at a young age (17). Since
clotting preparations became available, the life
expectancy has increased to an almost normal life
span, which makes it possible to study the occurrence
of other causes of death, i.e. coronary heart disease.
Table 3 lists the five most recent studies on mortality
in hemopilia, comprising a total of 1214 deaths.
Among 1214 deaths in hemophilia patients, only
5.4 percent was caused by coronary heart disease. In
the general population in the Netherlands, which
among the industrialised countries has an
intermediate incidence of CHD, 21 percent of all
deaths can be attributed to coronary disease. Since the
proportional mortality of CHD may have been
influenced by competing causes of deaths, i.e.
bleeding, and the lower mean age of hemophilia
patients, we compared CHD mortality with cancer
mortality, the ratio of which is fairly constant ove age.
The ratio of CHD deaths to cancer deaths was 0.8,
whereas in the general population of many countries
CHD mortality exceeds cancer mortality (ratio CHD
to cancer deaths: USA 1.5, The Netherlands 0.8).
In our study on mortality in hemophilia we
followed 717 patients from 1973 to 1986, and
calculated the expected number of deaths of each
cause by application of the mortality rates of the
general population (18). This patient-year method
largely avoids the problem of competing causes,
whereas age is adjusted for. The observed to expected
ratio (SMR) for coronary heart disease was 0.20, i.e.
CHD mortality was reduced by 80 percent.
The major drawback in these studies is that
hemophilia patients suffer from a chronic disease, that
affects life in many ways. One may wonder whether
the factor VIII deficiency is the only difference
between these patients and the general population,
and whether other factors in these patients, e.g.
lifestyle, might influence the incidence of CHD. To
this effect, we studied the major risk factors for CHD,
blood pressure, cholesterol, smoking and Quetelet
index in 95 hemophilia patients, and compared their
CHD risk profile based on these factors with data
TABLE 3. - Mortality in hemophilia patients.
deaths in hemophilia patients
Study
Larsson [10]
Rizza [15]
Schiller [19]
Aronson [1]
Rosendaal [18]
country
Sweden
United Kingdom
(East-) Germany
USA
The Netherlands
total
87
89
52
949
43
CHD
%
12.6
1.1
1.9
5.5
2.3
cancer
%
4.6
7.9
1.9
6.0
34.9
ratio CHD/
cancer
2.8
0.1
1.0
0.9
0.1
Total 1214 5.4 6.9 0.8
Two studies (18, 19) also include hemophilia B patients (factor IX deficiency), who constitute about 15% of the total number of
hemophilia patients.
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from the general population (16). Although
difFerences in some of the risk factors were found
(higher blood pressures, lower total cholesterol), the
overall age-adjusted risk profile of the hemophilia
patients was approximately equal to that of the general
population. This lends further support to the notion
that it is indeed the low factor VIII level that protects
hemophilia patients against coronary heart disease.
CONCLUSION
There can be little doubt that the hemostatic
System is a major determinant of coronary heart
disease. From several types of studies, in the general
population, among patients with myocardial infarction
and among hemophilia patients, it has become clear
that clotting factor VIII plays an important role in the
pathogenesis of coronary heart disease.
Myocardial infarction is the result of many years
of atherosclerosis followed by arterial thrombosis. It is
unresolved whether the hemostatic System plays a role
in plaque formation or only in the final thrombosis
after plaque rupture.
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In plasma, Factor VIII is bound to its carner protem, von Willebrand Factor (vWF) Therefore,
the levels of these two factors vary together From studies m the general population, m paüents with
coronary heart disease and in hemophiha paüents, an association between Factor VIII levels and
coronary heart disease clearly emerges
INTRODUCTION
In the last decade it has become mcreasingly clear
that the hemostatic System plays a central role in the
development of coronary heart disease Not only has it
been demonstrated that coronary thrombosis is the
final and crucial event m myocardial mfarction (4, 5),
but also that hypercoagulability, i e high blood levels
of clottmg factors, are long term predictors of
coronary heart disease In the Nortwick Park Heart
Study it was prospectively shown that the levels of
clottmg factor VII and fibnnogen were strongly
related to the nsk of the development of myocardial
mfarction (12) These associations have been
confirmed m several other studies (2, 8, 23)
The presence of occlusmg thrombi m the
coronary artenes causing myocardial mfarction and
the predictive power of factor VII and fibronogen
establish the role of coagulation in coronary heart
disease With regard to fibrmogen, it has to be noted
that this protem contibutes substantially to blood
viscosity Hyperfibrmogenemia, therefore, leads to
hyperviscosity äs well äs hypercoagulability, which
may also explam the association with coronary heart
disease Further evidence for the clottmg System äs a
major determmant of coronary heart disease is
provided by the efficacy of oral anticoagulation in the
prevention of recurrent myocardial mfarction (20, 21)
In this paper we will consider the role of clottmg
factor VIII In response to tissue damage, blood
coagulation is imtiated by factor VII in combrnation with
cell surface bound tissue factor and phospholipid
surfaces In the initial phase factor X is activated and the
product, factor Xa activates factor VII mto factor "VTIa,
which has higher enzymatic potency that its precursor
Subsequently, the process follows the alternative pathway
where factor IX is activated by factor Vlla and factor X is
activated predommantly by factor IXa Fmally, factor
Xa activates prothrombm mto thrombin, the major
effector enzyme of the System (Figure 1)
The three enzymes Vlla, IXa and Xa require non-
enzymatic cofactors for their catalytic efficiency tissue
factor, factor VIII and factor V, respectively A
powerful positive feedback is provided by thrombin
activating factor VIII to Villa and factor V to Va
Since hemophiha A, hereditary factor VIII deficiency,
is associated with severe bleedmg, we know that factor
VIII is an essential component of the system
In plasma, factor VIII is bound to its carner
protem, von Willebrand factor (vWF) The levels of
these two factors covary and are related to blood
group Smce von Willebrand factor may itself be a
determmant of the nsk of CHD, given its function m
promotmg platelet adhesion, this covanation poses a
problem m evaluatmg studies on factor VIII levels and
coronary heart disease
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Figure 1. - The central pari of the clotting System.
Blood group, factor VIII and von Willebrand factor
Since von Willebrand factor is the carrier protein
of factor VIII, low levels of vWF äs in von
Willebrand's disease, cause a shortened half-life of
factor VIII and low plasma levels of factor VIII. This
forms the main cause of bleeding problems in von
Willebrand's disease. In the normal population the
levels of both factors also vary together, and are
related to blood group. Table l shows this relation and
covariation by the results of a study we performed on
93 healthy volunteers.
In several studies a higher risk of coronary heart
disease (by about 20 percent), äs well äs of
atherosclerosis, has been demonstrated for individuals
with non-O blood groups (9, 13, 22). This is likely to
be caused by the higher levels of von Willebrand
factor and factor VIII in these individuals (14).
TABLE 1. - Relation between blood group, FVIII and
vWf.
In this paper we will restrict ourselves to clotting
factor VIII. However, since platelet adhesion mediated by
von Willebrand factor may play a role in the pathogenesis
of myocardial infarction (6), this background Information
on the covariation of vWF and FVIII is essential in
interpreting the evidence on the relation between factor
VIII and coronary heart disease.
Types of studies
Three types of studies can be considered. First,
studies in the general population, in which baseline
measurements are associated with subsequent coronary
events. These are (prospective) cohort studies in initially
healthy individuals. Secondly, studies in patients with
coronary heart disease, in whom clotting factors are
measured after the disease has manifested itself. These
are studies in which the clotting factor levels of the
patients are compared to those of healthy controls.
Thirdly, studies in hemophilia patients, who lack factor
VIII. These are 'experiments of nature', in which the
frequency of coronary disease (or mortality) is compared
with the general population.
Cohort studies
At present there is only one completed
prospective cohort study in which factor VTII was
measured, The Northwick Park Heart Study (12),
whereas one study is still in progress (the PROCAM
study in Germany). Table 2 shows the relative risks for
myocardial infarction associated with different levels
of factor VIII that were observed in the 1500 men
followed in the Northwick Park Heart Study.
These results of the Northwick Park Heart Study
indicate that in the one third of the population with
the highest factor VIII levels, the risk of the
development of coronary heart disease may be äs
much äs 44 percent greater than in the one third of the
population with the lowest factor VIII levels, although
the association was not statistically significant (p =
0.2). Because of the covariation of factor VIII and von
Willebrand factor, this association might have been
brought about by a relation between vWF levels and
the risk of CHD. However, when mean values at entry
were compared for 15 cardiovascular deaths and 45
survivors, no differece in vWF levels was discerned (l 1).
Blood group
O non-O
(n = 40) (n = 53)
FVIII (IU / ml)
vWF (IlJ/ml)
Ratio FVIII / vWF
0.88
0.86
1.02
1.25
1.16
1.06
Normal mean for FVIII and vWF is 1.0 lU/ml. FVIII coagulant
activity (FVIILC) measured by a one-stage clotting assay, vWF
activity äs ristocetin cofactor activity (vWF:Rco) by the use of
formalin fixed platelets.
TABLE 2. - Risk of coronary heart disease and factor
VIII levels (Northwick Park Heart Study).
FVIII CHD relative risk
low
middle
high
27
36
39
1.00
1.33
1.44
The cohort was divided in thirds of the FVIII distribution. The
risk of CHD to the lowest third was calculated from the paper
under the assumption of equal follow-up time in all three groups.
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Studies in patients with coronary heart disease
If a high plasma concentration of factor VIII
increases the risk of CHD, one would expect higher
levels of factor VIII in patients with coronary disease
than in healthy individuals. Cucuianu and colleagues
reported elevated levels of FVIII and vWF shortly
after myocardial infarction (3). The observed clotting
factor levels in the patients were so high (two- to
fourfold increase) that the authors concluded that this
was most likely brought about by the infarction, either
äs the result of endothelial injury or äs a systemic
acute phase reaction. Haines et al. studied 272 patients
with myocardial infarction (7) and also observed
substantially elevated factor VIII levels (approx. 1.4
lU/ml, normal value 1.0 lU/ml) in these patients.
Subsequently, the patients were followed for one year.
The 68 patients who died had had a mean factor VIII
level of 1.65 lU/ml (at admission), whereas the 204
patients who were alive at one year had had a mean
factor VIII level of 1.27 lU/ml. Von Willebrand factor
levels were also higher in the patients than the
population mean, and also had prognostic value in the
one year follow-up. In this paper too it was discussed
that the raised clotting factor levels might have
resulted from the infarction, and that the extent of the
elevation might be a reflection of infarction size, thus
offering an alternative explanation than
hypercoagulability for the prognostic value of factor
VIII levels after myocardial infarction.
Studies in hemophilia patients
Hemophilia A, which accounts for 85% of all
cases of hemophilia, is a deficiency of factor VIII.
Factor VIII may be completely absent, äs in severe
hemophilia, or present to some extent, äs in moderate
and mild hemophilia. Von Willebrand factor and
platelet function is not affected in hemophilia. Until
the 1960s, before the introduction of cryoprecipitate,
hemophilia could not be adequately treated, and most
patients died of bleeding at a young age (17). Since
clotting preparations became available, the life
expectancy has increased to an almost normal life
span, which makes it possible to study the occurrence
of other causes of death, i.e. coronary heart disease.
Table 3 lists the five most recent studies on mortality
in hemopilia, comprising a total of 1214 deaths.
Among 1214 deaths in hemophilia patients, only
5.4 percent was caused by coronary heart disease. In
the general population in the Netherlands, which
among the industrialised countries has an
intermediate incidence of CHD, 21 percent of all
deaths can be attributed to coronary disease. Since the
proportional mortality of CHD may have been
influenced by competing causes of deaths, i.e.
bleeding, and the lower mean age of hemophilia
patients, we compared CHD mortality with cancer
mortality, the ratio of which is fairly constant ove age.
The ratio of CHD deaths to cancer deaths was 0.8,
whereas in the general population of many countries
CHD mortality exceeds cancer mortality (ratio CHD
to cancer deaths: USA 1.5, The Netherlands 0.8).
In our study on mortality in hemophilia we
followed 717 patients from 1973 to 1986, and
calculated the expected number of deaths of each
cause by application of the mortality rates of the
general population (18). This patient-year method
largely avoids the problem of competing causes,
whereas age is adjusted for. The observed to expected
ratio (SMR) for coronary heart disease was 0.20, i.e.
CHD mortality was reduced by 80 percent.
The major drawback in these studies is that
hemophilia patients suffer from a chronic disease, that
affects life in many ways. One may wonder whether
the factor VIII deficiency is the only difference
between these patients and the general population,
and whether other factors in these patients, e.g.
lifestyle, might influence the incidence of CHD. To
this effect, we studied the major risk factors for CHD,
blood pressure, cholesterol, smoking and Quetelet
index in 95 hemophilia patients, and compared their
CHD risk profile based on these factors with data
TABLE 3. - Mortality in hemophilia patients.
deaths in hemophilia patients
Study
Larsson [10]
Rizza [15]
Schiller [19]
Aronson [1]
Rosendaal [18]
country
Sweden
United Kingdom
(East-) Germany
USA
The Netherlands
total
87
89
52
949
43
CHD
%
12.6
1.1
1.9
5.5
2.3
cancer
%
4.6
7.9
1.9
6.0
34.9
ratio CHD/
cancer
2.8
0.1
1.0
0.9
0.1
Total 1214 5.4 6.9 0.8
Two studies (18, 19) also include hemophilia B patients (factor IX deficiency), who constitute about 15% of the total number of
hemophilia patients.
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from the general population (16). Although
differences in some of the risk factors were found
(higher blood pressures, lower total cholesterol), the
overall age-adjusted risk profile of the hemophilia
patients was approximately equal to that of the general
population. This lends further support to the notion
that it is indeed the low factor VIII level that protects
hemophilia patients against coronary heart disease.
CONCLUSION
There can be little doubt that the hemostatic
System is a major determinant of coronary heart
disease. From several types of studies, in the general
population, among patients with myocardial infarction
and among hemophilia patients, it has become clear
that clotting factor VIII plays an important role in the
pathogenesis of coronary heart disease.
Myocardial infarction is the result of many years
of atherosclerosis followed by arterial thrombosis. It is
unresolved whether the hemostatic System plays a role
in plaque formation or only in the final thrombosis
after plaque rupture.
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